Top Markets
Coin of the day
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Rankning i aktier #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Aktiekurs
$14.07
Senast synkroniserad: 2026-08-28
Marknadsvärde
$1.18B
Förändring (1 dag)
-4.41%
Förändring (1 år)
145.13%
Land
US
Handel Corvus Pharmaceuticals, Inc. (CRVS)

Kategori

Antal utestående aktier för Corvus Pharmaceuticals, Inc. (CRVS)
Antal utestående aktier per August 2026: 0
Enligt de senaste finansiella rapporterna och aktiekursen för Corvus Pharmaceuticals, Inc. är det aktuella antalet utestående aktier 0. I slutet av August 2026 hade företaget 0 utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Corvus Pharmaceuticals, Inc. (CRVS) från 2026 till 2026
Utestående aktier vid slutet av varje år
År Utestående aktier Ändra
Inte tillräckligt med data för de angivna datumen.
Utestående aktier för liknande företag eller konkurrenter
Företag Utestående aktier Skillnad Land
253.90M -
US
62.19M -
NL
478.91M -
AU
396.00M -
US
- -
CH